Juno Therapeutics (JUNO) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
March 1, 2017 4:05 PM ESTNine product candidates in clinical trials against eight different targets
Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017
Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL
Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting
2016 year end cash position of $922.3 million
2017 cash burn guidance of $270 million to $300 million, including $22 million to $27 million in capital expenditures
Conference call today at 5:00 p.m. Eastern Time
... More